Drug Laws and Policy: Criminalization, Decriminalization, and the War on Drugs

Origins of Drug Prohibition in America

Drug criminalization in the United States has roots in the early twentieth century. The Pure Food and Drug Act of 1906 required labeling of patent medicines containing opiates, alcohol, and other substances, reducing unknowing consumption. The Harrison Narcotics Tax Act of 1914 imposed registration and taxation requirements on opium and coca products, effectively making non-medical use illegal by requiring a physician's prescription. The Eighteenth Amendment (1919) prohibited alcohol, a failed experiment in criminal prohibition that was reversed by repeal in 1933 — but its lessons about prohibition's consequences did not prevent escalating drug criminalization.

The Marihuana Tax Act of 1937 effectively criminalized cannabis, driven by a campaign linking marijuana to crime, violence, and racial minorities — appeals historians have characterized as xenophobic and scientifically unfounded. The racial dimensions of early drug laws were explicit in some cases: opium bans initially targeted Chinese immigrant communities, cocaine restrictions were partially driven by racist fears about African Americans, and anti-marijuana campaigns explicitly linked the drug to Mexican immigrants. These origins embedded racial disparities into drug enforcement that have persisted and compounded through subsequent decades of policy.

The Controlled Substances Act and Drug Scheduling

The modern federal drug control framework was established by the Controlled Substances Act (CSA) of 1970, enacted as part of the Comprehensive Drug Abuse Prevention and Control Act. The CSA created a scheduling system classifying drugs into five categories based on their medical use, abuse potential, and safety. Schedule I drugs — including heroin, LSD, psilocybin, MDMA, and marijuana — are deemed to have no accepted medical use, high abuse potential, and lack of accepted safety even under medical supervision. Schedule II drugs (cocaine, methamphetamine, oxycodone, fentanyl) have high abuse potential but accepted medical uses. Schedules III through V cover progressively lower-risk substances with accepted medical uses.

The scheduling system has been heavily criticized for political rather than scientific basis. Marijuana's Schedule I classification — maintained despite decades of evolving scientific evidence on its medical utility — has been a particular flashpoint. The DEA has repeatedly declined to reschedule cannabis, though the Biden administration initiated a review process in 2023 and the DEA proposed rescheduling marijuana to Schedule III in 2024. Critics note that scheduling decisions have been shaped by politics and racial anxieties rather than pharmacology: alcohol and tobacco, which cause more health harm than many scheduled substances, are entirely outside the scheduling framework.

The War on Drugs: Nixon to Reagan

President Richard Nixon declared a "War on Drugs" in 1971, identifying drug abuse as "public enemy number one." This framing established drug control as a criminal enforcement priority rather than a public health matter. Nixon's former domestic policy chief John Ehrlichman later acknowledged (in a 2016 Harper's Magazine interview) that the War on Drugs was conceived as a political strategy targeting Nixon's perceived enemies — the antiwar left and Black Americans — by associating those communities with marijuana and heroin respectively and then criminalizing them.

President Ronald Reagan dramatically escalated the War on Drugs in the 1980s, driven partly by the crack cocaine epidemic that devastated urban communities. The Anti-Drug Abuse Act of 1986 established the notorious 100-to-1 sentencing disparity between crack and powder cocaine: a conviction for five grams of crack triggered a five-year mandatory minimum, while the same sentence required 500 grams of powder cocaine. Since crack was used predominantly by Black Americans while powder cocaine was used more often by white Americans, this disparity produced dramatically unequal sentences for pharmacologically identical conduct and contributed significantly to the mass incarceration of Black Americans. The Fair Sentencing Act of 2010 reduced but did not eliminate this disparity (to 18-to-1), and the First Step Act of 2018 made the reduction retroactive.

Mass Incarceration and Racial Disparities

The United States imprisons more people than any other country in the world, both in absolute numbers and per capita. Drug laws and their enforcement have been a primary driver of this mass incarceration. The U.S. prison population grew from approximately 300,000 in 1970 to over 2.3 million by 2008, with drug offenses accounting for a substantial portion of federal and state sentences. Mandatory minimum sentencing laws, which require judges to impose fixed prison terms regardless of individual circumstances, removed judicial discretion and contributed to sentence inflation throughout the 1980s and 1990s.

The racial disparities in drug enforcement are stark and well-documented. Studies consistently show that Black and white Americans use illicit drugs at roughly similar rates, yet Black Americans are arrested for drug offenses at significantly higher rates, prosecuted more often and more aggressively, and sentenced to longer terms when convicted. In 2018, Black Americans represented approximately 33 percent of drug arrests despite comprising 13 percent of the population and approximately similar usage rates to white Americans. These disparities are attributed to differential policing — heavy police presence in predominantly Black neighborhoods rather than suburban and rural areas with similar drug use rates — combined with prosecutorial discretion, bail system dynamics that pressure pretrial detention into guilty pleas, and sentencing guidelines that amplify racial differences at each stage of the process.

Decriminalization, Legalization, and Reform Movements

Beginning in the 1970s and accelerating dramatically in the 2010s and 2020s, drug policy reform has moved toward decriminalization and legalization. Decriminalization removes criminal penalties (typically prison) for personal possession while maintaining prohibition — possession becomes a civil infraction subject to fines, similar to a traffic ticket, with no criminal record consequence. Legalization goes further, creating a regulated market for production, distribution, and sale. Portugal's 2001 decriminalization of all personal drug use — combined with investment in treatment and harm reduction — has been cited as a successful model, associated with reduced HIV infections, drug-related deaths, and incarceration without increases in drug use rates.

In the United States, cannabis legalization has advanced rapidly at the state level. As of 2024, recreational marijuana is legal in 24 states and Washington D.C., representing over half the U.S. population. The legal cannabis industry generates billions in tax revenue and has created hundreds of thousands of jobs. However, federal prohibition continues, creating legal conflicts and barriers to banking access for cannabis businesses. Psilocybin therapy has been legalized for therapeutic use in Oregon and Colorado, and several cities have decriminalized psychedelic substances. Harm reduction policies — including needle exchange programs, naloxone distribution to prevent opioid overdose deaths, and safe consumption sites — have expanded despite political opposition, driven by the public health emergency created by the opioid epidemic which has killed hundreds of thousands of Americans since the late 1990s.

The Opioid Crisis and Evolving Enforcement

The opioid epidemic, beginning with the overprescription of OxyContin and other prescription opioids in the late 1990s and escalating with heroin and illicit fentanyl use, has caused over 500,000 overdose deaths in the United States between 1999 and 2023. The epidemic affected predominantly white, rural and suburban communities at its outset, and observers noted that policy responses — emphasizing treatment and public health rather than criminalization — differed from the crack cocaine crisis's enforcement-focused response, highlighting persistent racial disparities in how drug epidemics are framed and addressed.

The legal accountability dimension of the opioid crisis has been extensive. Purdue Pharma, the maker of OxyContin, paid approximately $8 billion in a federal settlement in 2020 and filed for bankruptcy. McKesson, Cardinal Health, and AmerisourceBergen — major pharmaceutical distributors — reached a $21 billion settlement with states and local governments in 2022. The Sackler family, owners of Purdue, reached separate settlements totaling billions, though the Supreme Court's 2024 ruling in Harrington v. Purdue Pharma blocked a bankruptcy provision shielding non-debtor Sackler family members from civil liability. These cases reflect growing recognition that corporate misconduct — not merely individual addiction — drove the opioid crisis, and that civil and criminal accountability for corporate actors is essential to addressing drug-related harm at its sources.